LEON's FR-JET Technology Enables High-Concentration mRNA-LNP Manufacturing with Enhanced In Vivo Activity
Key Insights
A peer-reviewed study published in Pharmaceutics demonstrates that LEON (search)'s FR-JET modular mixer can produce lipid nanoparticles (search) at concentrations above 50 mg/mL while maintaining product quality and enhancing in vivo potency.
The technology addresses key manufacturing bottlenecks by enabling process intensification, reducing downstream processing time, and eliminating the rate-limiting ultrafiltration step in tangential flow filtration.
Higher concentration formulations showed improved particle morphology with more uniform solid-core structures and demonstrated colloidal stability for 3-6 months across different buffer systems.
A breakthrough study published in Pharmaceutics reveals that LEON (search)'s FR-JET modular mixer technology can produce highly concentrated lipid nanoparticles (search) (LNPs (search)) at concentrations exceeding 50 mg/mL, significantly surpassing current industry standards while enhancing biological activity in vivo. The research addresses critical manufacturing bottlenecks that have limited the scalability and efficiency of mRNA (search)-LNP production.
Overcoming Manufacturing Limitations
Traditional microfluidic systems face significant operational challenges including frequent clogging, poor robustness, and scalability barriers. Conventional T-mixers often exhibit inconsistent reproducibility, particularly when scaling-out strategies are employed, which can complicate manufacturing processes. Dr. Blerina Shkodra, the study's lead author, emphasized that "LNP manufacturing challenges are not solely scientific, but are also largely operational in nature."
The FR-JET technology demonstrates robust mixing capabilities that unlock process intensification while supporting predictable and direct scale-up, addressing these fundamental limitations.
Enhanced Performance Through High-Concentration Formulation
The study revealed multiple advantages of formulating LNPs (search) at significantly higher lipid mixture concentrations:
Manufacturing Efficiency
Process intensification through higher starting material concentrations can shorten or eliminate the initial rate-limiting ultrafiltration step in tangential flow filtration (TFF). This advancement reduces overall downstream process time and buffer consumption during diafiltration, streamlining the manufacturing workflow.
Improved Product Performance
Cryogenic transmission electron microscopy (Cryo-TEM) analysis revealed more uniform, solid-core particles when using higher concentration formulations. The increased lipid and RNA concentrations demonstrated enhanced in vivo potency, which may translate into improved tolerability and more efficient dosing strategies for patients.
Superior Product Quality
Higher solid-core fractions indicate more uniform particle morphologies, alongside demonstrated colloidal stability maintained for 3 to 6 months across two different buffer systems. This stability profile represents a significant improvement for storage and distribution logistics.
Commercial and Clinical Implications
The technology supports smoother translation from formulation development to manufacturing scale, enabling more robust processes and easier technology transfer. Dr. Wolfgang Hofmann, CEO of LEON (search), stated that "this peer-reviewed study validates the science behind the FR-JET technology and confirms that our commercially available manufacturing systems are making a big difference."
Broader Context of mRNA-LNP Manufacturing
The advancement comes at a critical time when mRNA (search) therapeutics have evolved from experimental tools to effective mechanisms for producing vaccines, cancer (search) therapies, and therapeutic proteins. LNPs (search) serve as essential carriers that protect mRNA from degradation and ensure efficient cellular uptake. However, traditional bulk methods such as ethanol injection or vortexing have resulted in batch inconsistencies and lack of control over particle size.
Microfluidic systems operate in a laminar regime where diffusion and hydrodynamic focusing control assembly, allowing fast, precise, and controlled mixing of lipid and aqueous phases at predetermined flow rates and ratios. This level of control enables optimization and ensures reproducibility at industrial scales.
Technology Portfolio and Future Outlook
LEON (search)'s equipment portfolio includes NANOscreen for formulation screening, NANOlab for process development, and NANOme and NANOus systems for GMP manufacture. These systems accommodate both individualized scales and commercial production, with the company providing additional formulation and process development services.
The study marks what Hofmann describes as "the beginning of a new phase for LNP manufacturing" and sets the foundation for LEON (search)'s planned developments in 2026. The technology aims to empower pharmaceutical companies, biotechnology firms, research institutes, and contract development and manufacturing organizations to capitalize on advancements in advanced therapies.